AR071452A1 - Inhibidores de hsp90 - Google Patents

Inhibidores de hsp90

Info

Publication number
AR071452A1
AR071452A1 ARP090100342A ARP090100342A AR071452A1 AR 071452 A1 AR071452 A1 AR 071452A1 AR P090100342 A ARP090100342 A AR P090100342A AR P090100342 A ARP090100342 A AR P090100342A AR 071452 A1 AR071452 A1 AR 071452A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
heterobicycloaryl
bicycloaryl
heteroaryl
Prior art date
Application number
ARP090100342A
Other languages
English (en)
Inventor
Wolfgang Reinhard Lu Notz
Young K Chen
Jeffrey A Stafford
Erick W Co
Prasuna Guntupalli
Huong-Thu Ton-Nu
John D Lawson
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR071452A1 publication Critical patent/AR071452A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)

Abstract

Composiciones farmacéuticas, kits y artículos de fabricacion que comprenden dichos compuestos; métodos e intermediarios utiles para producir los compuestos; y métodos de uso de dichos compuestos. Reivindicacion 1: Un compuesto de la formula seleccionada del grupo que consiste en formulas (1), (2), (3) o (4), o uno de sus tautomeros, estereoisomeros o sales aceptables desde el punto de vista farmacéutico, en los cuales X es O, NR8 o CR9R9'; R1 se selecciona del grupo que consiste en hidrogeno, carbonilo, hidroxicarbonilo, oxicarbonilo, aminocarbonilo, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, heteroalquilo C1-10, hidroxialquilo C1-10, alcoxialquilo C1-10, aminoalquilo C1-10, iminoalquilo C1-10, carbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, carbonilaminoalquilo C1-10, tiocarbonilalquilo C1-10, hidroxilcarbonilalquilo C1-10, aminocarbonilalquilo C1-10, aminosulfonilalquilo C1-10, sulfonilaminoalquilo C1-10, alquilsulfonilamino C1-6-alquilo C1-10, cicloalquil C3-12-alquilo C1-5, hetero cicloalquil C3-12-alquilo C1-10, arilalquilo C1-10, heteroaril C1-10-alquilo C1-5, bicicloaril C9-12-alquilo C1-5, heterobicicloaril C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno no sustituido o sustituido; R2 se selecciona del grupo que consiste en hidrogeno, halo, ciano, tio, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, amino, alquilamino C1-10, sulfonilamino, aminosulfonilo, sulfonilo, sulfinilo, alquilo C1-10, hetero alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12-alquilo C1-5, hetero cicloalquil C3-12-alquilo C1-10, arilalquilo C1-10, heteroaril C1-10-alquilo C1-5, bicicloaril C9-12-alquilo C1-5, heterobicicloaril C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12 cada uno sustituido o no sustituido; R3 se selecciona del grupo que consiste en hidrogeno, halo, nitro, ciano, tio, oxi, hidroxi, carboniloxi, alcoxi C1-10, ariloxi C4-12, heteroariloxi C1-10, carbonilo, oxicarbonilo, aminocarbonilo, amino, alquilamino C1-10, sulfonilamino, aminosulfonilo, sulfonilo, sulfinilo, alquilo C1-10, alquenilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, heteroalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12-alquilo C1-5, hetero cicloalquil C3-12-alquilo C1-10, arilalquilo C1-10, heteroaril C1-10-alquilo C1-5, bicicloaril C9-12-alquilo C1-5, heterobicicloaril C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-15, heteroC1-14cicloalquilo, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-15, heteroC1-14arilo, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno no sustituido o sustituido; R4 se selecciona del grupo que consiste en hidrogeno, carbonilo, oxicarbonilo, amino, alquilamino C1-10, sulfonilamino, aminosulfonilo, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12-alquilo C1-5, heterocicloalquil C3-12-alquilo C1-10, arilalquilo C1-10, heteroaril C1-10-alquilo C1-5, bicicloaril C9-12-alquilo C1-5, heterobicicloaril C8-12- alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12 , bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R5 y R5' se seleccionan cada uno en forma independiente del grupo que consiste en hidrogeno, ciano, carbonilo, oxicarbonilo, aminocarbonilo, sulfonilo, sulfinilo, alquilo C1-10, haloalquilo C1-10, hidroxialquilo C1-10, carbonilalquilo C1-10, tiocarbonilalquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, heteroalquilo C1-10, iminoalquilo C1-10, cicloalquil C3-12-alquilo C1-5, hetero cicloalquil C3-12-alquilo C1-10, arilalquilo C1-10, heteroaril C1-10-alquilo C1-5, bicicloaril C9-12-alquilo C1-5, heterobicicloaril C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R6 y R6' se seleccionan cada uno en forma independiente del grupo que consiste en hidrogeno, halogeno, ciano, alquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, heteroalquilo C1-10, cicloalquil C3-12-alquilo C1-5, hetero cicloalquil C3-12-alquilo C1-10, arilalquilo C1-10, heteroaril C1-10-alquilo C1-5, bicicloaril C9-12-alquilo C1-5, heterobicicloaril C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido, siempre que R6' esté ausente cuando A es CR5R5'; R7 se selecciona del grupo que consiste en hidrogeno, ciano, sulfonilo, sulfinilo, alquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, azaalquilo C1-10, oxaalquilo C1-10, cicloalquil C3-12-alquilo C1-5, heterocicloalquil C3-12-alquilo C1-10, arilalquilo C1-10, heteroaril C1-10-alquilo C1-5, bicicloaril C9-12-alquilo C1-5, heterobicicloaril C8-12- alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12 , bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; R8 se selecciona del grupo que consiste en hidrogeno, alquilo C1-10, hidroxialquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, cicloalquil C3-12-alquilo C1-5, hetero cicloalquil C3- 12-alquilo C1-10, arilalquilo C1-10, heteroaril C1-10-alquilo C1-5, bicicloaril C9-12-alquilo C1-5, heterobicicloaril C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada uno sustituido o no sustituido; y R9 y R9' se seleccionan cada uno en forma independiente del grupo que consiste en hidrogeno, sulfonilamino, aminosulfonilo, sulfonilo, sulfinilo, alquilo C1-10, hidroxialquilo C1-10, sulfonilalquilo C1-10, sulfinilalquilo C1-10, heteroalquilo C1-10, cicloalquil C3-12, alquilo C1-5, hetero cicloalquil C3-12-alquilo C1-10, arilalquilo C1-10, heteroaril C1-10-alquilo C1-5, bicicloaril C9-12-alquilo C1-5, heterobicicloaril C8-12-alquilo C1-5, heteroalquilo C1-10, cicloalquilo C3-12, heterocicloalquilo C3-12, bicicloalquilo C9-12, heterobicicloalquilo C3-12, arilo C4-12, heteroarilo C1-10, bicicloarilo C9-12 y heterobicicloarilo C4-12, cada un sustituido o no sustituido; siempre que para la Formula 2, cuando X es O, R1 es alquilo C1-6 sustituido con por lo menos dos grupos hidroxilo.
ARP090100342A 2008-02-01 2009-02-02 Inhibidores de hsp90 AR071452A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2572508P 2008-02-01 2008-02-01
US10159508P 2008-09-30 2008-09-30

Publications (1)

Publication Number Publication Date
AR071452A1 true AR071452A1 (es) 2010-06-23

Family

ID=40436400

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100342A AR071452A1 (es) 2008-02-01 2009-02-02 Inhibidores de hsp90

Country Status (26)

Country Link
US (4) US20110053873A1 (es)
EP (1) EP2252595B1 (es)
JP (1) JP5524084B2 (es)
KR (1) KR20100116206A (es)
CN (1) CN101983191B (es)
AR (1) AR071452A1 (es)
AU (1) AU2009208947B2 (es)
BR (1) BRPI0906598A2 (es)
CA (1) CA2713658C (es)
CL (1) CL2009000228A1 (es)
CR (1) CR11659A (es)
DO (1) DOP2010000236A (es)
EA (1) EA019156B1 (es)
EC (1) ECSP10010434A (es)
ES (1) ES2475206T3 (es)
GE (1) GEP20125718B (es)
IL (1) IL207227A0 (es)
MA (1) MA32104B1 (es)
MX (1) MX2010008269A (es)
MY (1) MY150596A (es)
NZ (1) NZ587207A (es)
PE (1) PE20091371A1 (es)
SG (1) SG187502A1 (es)
TW (1) TW200946531A (es)
WO (1) WO2009097578A1 (es)
ZA (1) ZA201005435B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617852A2 (pt) 2005-10-25 2011-08-09 Shionogi & Co compostos derivados de aminodi-hidrotiazina assim como composições contendo os mesmos
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
ATE553107T1 (de) 2007-03-01 2012-04-15 Chugai Pharmaceutical Co Ltd Makrocyclische verbindung
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
ES2475206T3 (es) * 2008-02-01 2014-07-10 Takeda Pharmaceutical Company Limited Derivados de oxima como inhibidores de HSP90
WO2009151098A1 (ja) 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
AU2011321427A1 (en) 2010-10-29 2013-05-02 Shionogi & Co., Ltd. Naphthyridine derivative
JPWO2012147763A1 (ja) 2011-04-26 2014-07-28 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
ITTO20111013A1 (it) 2011-11-03 2013-05-04 Dac Srl Composti farmaceutici
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
WO2014107655A1 (en) * 2013-01-07 2014-07-10 St. Jude Children's Research Hospital Use of small molecule unfolder protein response modulators to treat tumors with active sonic hedgehog (ssh) signaling due to smoothened (smo) mutation
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
WO2015023593A1 (en) 2013-08-12 2015-02-19 Emory University Progesterone phosphate analogs and uses related thereto
CN107110869B (zh) 2014-09-17 2021-08-10 纪念斯隆-凯特琳癌症中心 Hsp90-靶向炎症和感染成像及治疗
US9868738B2 (en) 2014-09-19 2018-01-16 Merck Sharp & Dohme Corp. Diazine-fused amidines as BACE inhibitors, compositions, and their use
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
CN110996918A (zh) * 2017-04-24 2020-04-10 萨缪斯治疗股份有限公司 Hsp90抑制剂口服配制品和相关方法
EP4374858A2 (en) 2017-05-26 2024-05-29 Cancer Research Technology Limited Benzimidazolone derived inhibitors of bcl6
JP2020534283A (ja) * 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． システインプロテアーゼのタンパク質阻害剤を介した自然転移の阻害
CN112544621B (zh) * 2020-04-13 2021-10-15 辽宁先达农业科学有限公司 一种制备2-(4-氯苯氧基)-丙氧胺的方法
CN111671749A (zh) * 2020-06-12 2020-09-18 重庆医科大学 双香豆素在制备HBx蛋白稳定性抑制剂中的用途
CN112661668B (zh) * 2020-12-31 2023-07-28 辽宁先达农业科学有限公司 一种n-取代酰胺类化合物及其制备方法
CN114259564B (zh) * 2021-11-30 2023-03-14 清华大学 Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用
CN115073458A (zh) * 2022-07-04 2022-09-20 山东致泰医药技术有限公司 一种阿维巴坦钠的制备方法
CN115381816A (zh) * 2022-08-04 2022-11-25 武汉市金银潭医院(武汉市传染病医院) Ver50589在制备抗肠道病毒71型药物中的应用
CN117907491B (zh) * 2024-03-12 2024-06-04 中国人民解放军军事科学院军事医学研究院 基于双衍生化技术的脱碱基位点lc-ms/ms分析方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA762455A (en) 1962-03-22 1967-07-04 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Pyrido-pyrimidines
DE1197466B (de) 1962-03-22 1965-07-29 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen
GB8912336D0 (en) 1989-05-30 1989-07-12 Smithkline Beckman Intercredit Compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
AU763839B2 (en) 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2001070229A1 (en) * 2000-03-23 2001-09-27 Merck & Co., Inc. Thrombin inhibitors
US20030229113A1 (en) 2000-03-24 2003-12-11 Koji Hashimoto Keratinocyte growth inhibitors and hydroxamic acid derivatives
JP2004505044A (ja) 2000-07-28 2004-02-19 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 細胞増殖性障害およびウイルス感染の治療方法
JPWO2002015925A1 (ja) 2000-08-22 2004-07-08 協和醗酵工業株式会社 アポトーシスの制御方法およびアポトーシス制御ポリペプチド
US7439359B2 (en) * 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
CA2440809A1 (en) * 2001-03-01 2002-09-12 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
KR20020089883A (ko) 2001-05-25 2002-11-30 주식회사 지인텍 마사지 장치
HUP0700040A2 (en) * 2001-06-28 2007-05-29 Essential Therapeutics Fused pyrimidines as d-alanyl-d-alanine ligase inhibitors, and process for producing them
JP2005139066A (ja) * 2001-12-14 2005-06-02 Hsp Research Institute Inc ２、３−ジヒドロ−１ｈ−キノリン−４−オンオキシム誘導体および熱ショック蛋白質発現誘導阻害剤
JPWO2003068776A1 (ja) 2002-02-15 2005-06-02 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
EP1511738A4 (en) 2002-05-17 2007-05-09 Scios Inc TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS
AU2003282512A1 (en) 2002-10-22 2004-05-13 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Methods of reducing the activity of and reducing the concentration of a mutant kit protein
EP1457499A1 (en) 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20070004674A1 (en) * 2003-08-22 2007-01-04 Kyowa Hakko Kogyo Co. Ltd. Remedy for diseases associated with immunoglobulin gene translocation
ATE433974T1 (de) 2003-09-19 2009-07-15 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
WO2005070929A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
US8741578B2 (en) 2004-11-02 2014-06-03 The Regents Of The University Of California Methods of detecting chronic lymphocytic leukemia with Hsp90 and ZAP-70
AU2005302000A1 (en) 2004-11-02 2006-05-11 Conforma Therapeutics Corporation Methods and compositions for treating chronic lymphocytic leukemia
WO2006052795A2 (en) 2004-11-05 2006-05-18 University Of Rochester Methods of inhibiting the activity of hsp90 and/or aryl hydrocarbon receptor
WO2006078891A2 (en) 2005-01-21 2006-07-27 Neurogen Corporation Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives
US8211875B2 (en) 2005-02-02 2012-07-03 Nexgenix Pharmaceuticals Inc Local treatment of neurofibromas
JP2008536835A (ja) 2005-04-06 2008-09-11 アイアールエム・リミテッド・ライアビリティ・カンパニー ジアリールアミン含有化合物および組成物、ならびにステロイドホルモン核受容体のモジュレータとしてのそれらの使用
AU2006236557A1 (en) 2005-04-14 2006-10-26 Novartis Vaccines And Diagnostics Inc. 2-amino-quinazolin-5-ones as HSP90 inhibitors useful in treating proliferation diseases
EP1885369B1 (en) 2005-05-04 2015-09-23 Evotec AG Fused heterocyclic compounds, and compositions and uses thereof
WO2006124904A2 (en) 2005-05-16 2006-11-23 Geron Corporation Cancer treatment by combined inhibition of telomerase and hsp90 activities
WO2006138265A2 (en) 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
WO2007035963A2 (en) 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
US20070161670A1 (en) 2006-01-09 2007-07-12 Bristol-Myers Squibb Company Process for the preparation of substituted heterocycles
US7851468B2 (en) 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
AU2007254357B2 (en) 2006-05-16 2011-07-21 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
WO2007143630A2 (en) 2006-06-02 2007-12-13 Nexgenix Pharmaceuticals Treatment of neurofibromatosis with hsp90 inhibitors
US8163760B2 (en) 2006-06-22 2012-04-24 Prana Biotechnology Limited Use of pyridopyrimidine compounds in the treatment of gliomas
US20080160520A1 (en) * 2006-06-22 2008-07-03 Angelika Amon Methods and Composition for Diagnosing and Treating Cancer
WO2008021981A2 (en) 2006-08-09 2008-02-21 Nexgenix Pharmaceuticals, Llc. Local treatment of epidermal and dermal hyperproliferative lesions
WO2008045529A1 (en) 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
CN101535280B (zh) 2006-11-15 2012-06-27 健泰科生物技术公司 芳基磺酰胺化合物
WO2008116216A1 (en) 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
ES2475206T3 (es) * 2008-02-01 2014-07-10 Takeda Pharmaceutical Company Limited Derivados de oxima como inhibidores de HSP90

Also Published As

Publication number Publication date
US8071766B2 (en) 2011-12-06
SG187502A1 (en) 2013-02-28
PE20091371A1 (es) 2009-10-03
IL207227A0 (en) 2010-12-30
GEP20125718B (en) 2012-12-25
US20120264770A1 (en) 2012-10-18
CA2713658A1 (en) 2009-08-06
MA32104B1 (fr) 2011-02-01
BRPI0906598A2 (pt) 2015-07-07
AU2009208947A1 (en) 2009-08-06
EP2252595B1 (en) 2014-03-26
ES2475206T3 (es) 2014-07-10
CR11659A (es) 2010-12-15
JP2011511003A (ja) 2011-04-07
ECSP10010434A (es) 2010-09-30
US20090305998A1 (en) 2009-12-10
TW200946531A (en) 2009-11-16
EA201070912A1 (ru) 2011-08-30
CA2713658C (en) 2016-07-05
DOP2010000236A (es) 2010-09-30
EP2252595A1 (en) 2010-11-24
MX2010008269A (es) 2011-02-21
JP5524084B2 (ja) 2014-06-18
WO2009097578A1 (en) 2009-08-06
US20110053873A1 (en) 2011-03-03
KR20100116206A (ko) 2010-10-29
US20120172321A1 (en) 2012-07-05
CL2009000228A1 (es) 2009-07-24
US8618290B2 (en) 2013-12-31
CN101983191B (zh) 2013-11-20
CN101983191A (zh) 2011-03-02
MY150596A (en) 2014-01-30
NZ587207A (en) 2012-05-25
ZA201005435B (en) 2011-11-30
EA019156B1 (ru) 2014-01-30
AU2009208947B2 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
AR071452A1 (es) Inhibidores de hsp90
CO6321274A2 (es) Compuestos de pirazol acetamida n-sustituida como activadores de glucoquinasa
AR062366A1 (es) Derivados de pirazoles como inhibidores no nucleosidicos de la transcriptasa inversa, composiciones farmaceuticas
RU2015121431A (ru) Замещенные производные индол-5-ола и их терапевтическое применение
CO6160296A2 (es) Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol
CO6230984A2 (es) Inhibidores de cinasa mapk/erk
AR071729A1 (es) Inhibidores de quinasas simil polo (plk)
BRPI0909731A2 (pt) derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
CO6220970A2 (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos
AR055620A1 (es) Derivados de cicloalcano-carboxamidas
AR048055A1 (es) Derivados de pirimidina como inhibidores de dipeptidil peptidasa
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
RS53176B (en) KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS
AR060658A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
PE20141191A1 (es) Compuestos como inhibidores de bace
ES2546502T3 (es) 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
PE20130155A1 (es) Derivados de ariletinilo
AR082887A1 (es) Derivados de piridin-3-il-metil, y composiciones para la inhibicion de nampt
AR074790A1 (es) Derivados de isooxazol sustituidos, composiciones farmaceuticas y para el control de parasitos que los comprenden y su uso en metodos para controlar parasitos en y sobre animales de sangre caliente.
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR061847A1 (es) Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas.
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR047367A1 (es) Compuestos de tiourea sustituidos con azabenzofurano, inhibidores de replicacion viral
AR071739A1 (es) Inhibidores de transcriptasa reversa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal